List of Erivedge drug patents

Erivedge is owned by Genentech.

Erivedge contains Vismodegib.

Erivedge has a total of 3 drug patents out of which 0 drug patents have expired.

Erivedge was authorised for market use on 30 January, 2012.

Erivedge is available in capsule;oral dosage forms.

Erivedge can be used as method of using vismodegib to treat cancer in a mammal, method of using vismodegib to treat basal cell carcinoma.

The generics of Erivedge are possible to be released after 15 December, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7888364 GENENTECH Pyridyl inhibitors of hedgehog signalling
Nov, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9790183 GENENTECH Pyridyl inhibitors of hedgehog signalling
Sep, 2025

(2 years from now)

US9278961 GENENTECH Pyridyl inhibitors of hedgehog signalling
Dec, 2028

(5 years from now)

Drugs and Companies using VISMODEGIB ingredient

Market Authorisation Date: 30 January, 2012

Treatment: Method of using vismodegib to treat basal cell carcinoma; Method of using vismodegib to treat cancer in a mammal

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic